2,3,6-三氯-5-甲基吡啶 | 58584-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,3,6-三氯-5-甲基吡啶
• 英文名称: 2,5,6-trichloro-3-methylpyridine
• 英文别名: 2,3,6-trichloro-5-methyl-pyridine；2,3,6-Trichlor-5-methyl-pyridin；2,3,6-trichloro-5-methylpyridine；2,5,6-Trichlor-3-methyl-pyridin
• CAS: 58584-95-5
• 化学式: C₆H₄Cl₃N
• mdl: MFCD00661302
• 分子量: 196.463
• InChiKey: DBOPDFFTUIMICA-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92 °C
• 沸点：
  260.1±35.0 °C(Predicted)
• 密度：
  1.457±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2,3,6-三氯-5-甲基吡啶 在 盐酸 、 ammonium hydroxide 、 potassium permanganate 、 草酰氯 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 48.0h， 生成 2,5,6-三氯烟腈
  参考文献：
  名称：

  In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors

  摘要：

  Synthesis and biological evaluation of a series of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors was reported. Biochemical screening, followed by profile optimization, resulted in JAK2 inhibitors exhibiting good kinase selectivity, pharmacokinetic properties, physical properties and pharmacodynamic effects. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.053
• 作为产物：
  描述：

  3-甲基环戊烷-1,2-二胺 在 硫酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 2,3,6-三氯-5-甲基吡啶
  参考文献：
  名称：

  Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+/H+ exchanger

  摘要：

  Pyridine and benzene bioisosteres of amiloride were synthesized and evaluated for their inhibitory Potency against the sodium-hydrogen exchanger (NHE) involved in intracellular pH regulation. The inhibition of NHE was determined by using the platelet swelling assay (PSA) in which the swelling of human platelets was induced by their incubation in an acid buffer (pH 6.7). Additionally, the inhibitory potency of the most active compounds was assessed by measuring the inhibition of the EIPA-sensitive Na-22 (+) uptake (UIA) by human platelets after intracellular acidosis. The results indicated that several benzene derivatives and compounds bearing an carbonylguanidine moiety in the meta position of the pyridine nitrogen were much more potent than amiloride (PSA:IC50 = 43.5 muM, UIA:IC50 = 100.1 muM), but less than EIPA, a pyrazine NHE inhibitor (PSA:IC50=0.08 muM, UIA: IC50 - 0.5 muM). In both biological assays (2-amino-5-bromo-pyridine-3-carbonyl)guanidine (32) was the most active molecule (PSA: IC50 = 0.8 muM, UIA : IC50 = 0.8 muM). Our investigations demonstrated that the replacement of the pyrazine ring of amiloride e by a pyridine ora phenyl ring improved the NHE inhibitory potency (phenyl >pyridine >pyrazine). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00022-6

文献信息

• Pyrazolylaminopyridine Derivatives Useful as Kinases Inhibitors
  申请人：Davies Audrey

  公开号：US20080139561A1

  公开（公告）日：2008-06-12

  This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有以下式（I）的新化合物，其制药组合物以及它们的使用方法。这些新化合物提供了一种治疗癌症的方法。
• Pyrazolylaminopyridine derivatives useful as kinase inhibitors
  申请人：Astrazeneca AB

  公开号：US08324252B2

  公开（公告）日：2012-12-04

  This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有式（I）的新化合物、其制药组合物以及它们的使用方法。这些新化合物提供了治疗癌症的方法。
• PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
  申请人：AstraZeneca AB

  公开号：US20130090358A1

  公开（公告）日：2013-04-11

  This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

  本发明涉及具有公式（I）的新化合物，以及它们的药物组合物和使用方法。这些新化合物提供了治疗癌症的方法。
• Method for producing substituted pyridine derivatives
  申请人：ISHIHARA SANGYO KAISHA, LTD.

  公开号：EP0512436A1

  公开（公告）日：1992-11-11

  A method for producing a substituted pyridine derivative of the formula (II): wherein each of R¹, R², R³ and R⁴ is a hydrogen atom, a halogen atom or an alkyl group, and m is an integer of from 1 to 3, which comprises reducing a substituted trichloromethylpyridine derivative of the formula (I): wherein R¹, R², R³ and R⁴ are as defined above, with use of acetic acid, hydrochloric acid or sulfuric acid, as a proton donor, and zinc, tin or a mixture thereof, as a reducing agent.

  一种生产式 (II) 的取代吡啶衍生物的方法： 其中 R¹、R²、R³ 和 R⁴ 各为氢原子、卤素原子或烷基，且 m 为 1 至 3 的整数，该方法包括还原式 (I) 的取代的三氯甲基吡啶衍生物： 其中 R¹、R²、R³ 和 R⁴ 如上定义，使用乙酸、盐酸或硫酸作为质子供体，锌、锡或它们的混合物作为还原剂。
• 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11230556B2

  公开（公告）日：2022-01-25

  The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 6,5-融合杂芳基哌啶醚化合物，该化合物是 M4 毒蕈碱乙酰胆碱受体的异构调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。